Eton Pharmaceuticals, Inc. (ETON)
61.27
-0.09
(-0.15%)
USD |
NASDAQ |
Nov 20, 14:13
Eton Pharmaceuticals EPS Diluted (Quarterly) : 1.060 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.060 |
| June 30, 2026 | 0.3531 |
| March 31, 2026 | 0.0493 |
| December 31, 2025 | 0.0475 |
| September 30, 2025 | -0.0716 |
| June 30, 2025 | -0.0961 |
| March 31, 2025 | -0.0585 |
| December 31, 2024 | -0.0229 |
| September 30, 2024 | 0.0236 |
| June 30, 2024 | -0.118 |
| March 31, 2024 | -0.0315 |
| December 31, 2023 | -0.0876 |
| September 30, 2023 | -0.0225 |
| June 30, 2023 | 0.1755 |
| March 31, 2023 | -0.1042 |
| December 31, 2022 | 0.036 |
| September 30, 2022 | -0.12 |
| June 30, 2022 | -0.062 |
| March 31, 2022 | -0.2107 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.04 |
| September 30, 2021 | -0.2411 |
| June 30, 2021 | -0.08 |
| March 31, 2021 | 0.1927 |
| December 31, 2020 | -0.3229 |
| September 30, 2020 | -0.309 |
| June 30, 2020 | -0.2252 |
| March 31, 2020 | -0.4988 |
| December 31, 2019 | -0.1504 |
| September 30, 2019 | -0.2777 |
| June 30, 2019 | -0.1832 |
| March 31, 2019 | -0.4234 |
| December 31, 2018 | -2.239 |
| September 30, 2018 | -0.2067 |
| June 30, 2018 | -0.2179 |
| March 31, 2018 | -0.2133 |
| December 31, 2017 | -0.163 |
| September 30, 2017 | -0.1984 |
| June 30, 2017 | -0.1303 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Aquestive Therapeutics, Inc. | -0.1314 |
| Pfizer Inc. | 0.5637 |
| Amneal Pharmaceuticals, Inc. | -0.0646 |
| ANI Pharmaceuticals, Inc. | 1.510 |
| Corcept Therapeutics, Inc. | 1.010 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 35.25M |
| Revenue (Quarterly) | 57.92M |
| Total Expenses (Quarterly) | 22.68M |
| Enterprise Value | 1.738B |
| Gross Profit Margin (Quarterly) | 76.48% |
| Profit Margin (Quarterly) | 60.85% |
| Earnings Yield | 2.46% |
| Operating Earnings Yield | 2.06% |
| Normalized Earnings Yield | 2.464 |